|Last Price$9.18||Day Change (%)0.00%|
|Open Price$9.18||Day Change ($)0.00|
|Day Range9.18–9.18||52-Week Range9.11–9.42|
As of Fri 10/09/2015 | USD
Results from Merck’s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Syniverse Holdings SVR posted second-quarter results that mostly met our expectations. We are reiterating our opinion that this company has very little growth potential and no competitive advantage. We continue to be less than positive on the overall market for providing network services to ...
Three stocks we think investors should be wary of.